Trials / Terminated

TerminatedNCT05265975

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adult Patients With Relapsed/Refractory DLBCL and iNHL Who Are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (ASCT)

Status: Terminated
Phase: Phase 1 / Phase 2
Study type: Interventional
Enrollment: 54 (actual)

Sponsor: Antengene Corporation · Industry
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: Not accepted

Summary

A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with Relapsed/Refractory DLBCL and iNHL Who are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (A SCT).

Detailed description

Conditions

Interventions

Type	Name	Description
DRUG	ATG-010	Tablets,20mg, once a week: dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
DRUG	Lenalidomide	Oral administration,QD, Days 1-21 of each cycle
DRUG	Rituximab	Intravenous injection Days 1 of each cycle, Cycles 1-6

Timeline

Start date: 2022-04-07
Primary completion: 2024-12-31
Completion: 2024-12-31
First posted: 2022-03-04
Last updated: 2025-06-09

Locations

6 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05265975. Inclusion in this directory is not an endorsement.